Search Result

Results for "

GnRH+Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) ERK (1) GnRH Receptor (30) Histamine Receptor (1) Isotope-Labeled Compounds (3) Nuclear Factor of activated T Cells (NFAT) (6) PERK (1) Reference Standards (2)
By Research Areas:	Cancer (17) Endocrinology (19) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16168A

Degarelix 10+ Cited Publications FE 200486 free base	GnRH Receptor Apoptosis	Endocrinology Cancer
Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC₅₀ = 3 nM). Degarelix acetate Degarelix acetate (FE 200486) is used for the research of prostate cancer .

HY-P0009A

Cetrorelix Acetate 1 Publications Verification SB-75 acetate	GnRH Receptor	Neurological Disease Endocrinology
Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone *(GnRH)* receptor antagonist with an IC₅₀ of 1.21 nM .

HY-14369

Elagolix sodium NBI-56418 sodium	GnRH Receptor Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease Cancer
Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (K_D = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .

HY-14789

(R)-Elagolix NBI-56418	GnRH Receptor Nuclear Factor of activated T Cells (NFAT)	Endocrinology Cancer
Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (K_D = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .

HY-P3668

[D-Lys6]-LH-RH	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH acts as a *GnRH receptor* agonist .

HY-P0056A

Histrelin acetate	GnRH Receptor	Cancer
Histrelin acetate, a GnRH analogue, is a *GnRH Receptor* agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, endometriosis .

HY-134864

Lumigolix GnRH antagonist 2	GnRH Receptor	Endocrinology
Lumigolix (GnRH antagonist 2) (formula I) is a *GnRH receptor* antagonist that can be used for endometriosis research .

HY-P3641A

Kisspeptin 13 TFA	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-16168

Degarelix acetate FE 200486	GnRH Receptor	Cancer
Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC₅₀ = 3 nM). Degarelix acetate (FE 200486) is used for the research of prostate cancer .

HY-P3668A

[D-Lys6]-LH-RH TFA	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH TFA is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH TFA acts as a *GnRH receptor* agonist .

HY-P0056

Histrelin	GnRH Receptor	Cancer
Histrelin, a GnRH analogue, is a *GnRH Receptor* agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis .

HY-13699

NBI-42902	GnRH Receptor PERK	Others
NBI-42902 is an orally active, potent functional and competitive antagonist of *GnRH receptor* with an IC₅₀ value of 0.79 nM, a K_i value of 0.56 nM, respectively. NBI-42902 inhibits GnRH-stimulated inositol phosphate (IP) accumulation, Ca ²⁺ flux, and ERK1/2 activation. NBI-42902 inhibits serum luteinizing hormone (LH) in castrated male macaques. NBI-42902 can be used for research on sex-hormone-related diseases .

HY-107534

AG-045572	GnRH Receptor	Endocrinology
AG-045572 is a *GnRH receptor* antagonist with K_is of 6.0 nM and 3.8 nM for human and rat GnRH receptor, respectively. AG-045572 is metabolized by CYP3A and ressuppresses testosterone .

HY-P0009B

Cetrorelix diacetate SB-75 diacetate	GnRH Receptor	Neurological Disease Endocrinology
Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone *(GnRH)* receptor antagonist with an IC₅₀ of 1.21 nM .

HY-P3641

Kisspeptin 13	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-U00289

Opigolix ASP-1707	GnRH Receptor	Inflammation/Immunology Endocrinology
Opigolix (ASP-1707) is a Gonadotropin-releasing hormone (GnRH) receptor antagonist, used for the research of endometriosis and rheumatoid arthritis.

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a *GnRH* antagonist. Teverelix binds competitively and reversibly to *GnRH receptors*, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

HY-120767

Linzagolix choline KLH-2109 choline; OBE-2109 choline	GnRH Receptor	Inflammation/Immunology Cancer
Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the *GnRH* receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids .

HY-P2028

BIM 21009	GnRH Receptor	Cancer
BIM 21009 is a LHRH and *GnRH* receptor antagonist. BIM 21009 inhibits tumor growth .

HY-14369R

Elagolix sodium (Standard) NBI-56418 sodium (Standard)	Reference Standards GnRH Receptor	Endocrinology Cancer
Elagolix sodium (Standard) is the analytical standard of Elagolix sodium. This product is intended for research and analytical applications. Elagolix sodium is a human *GnRH receptor* (GnRHR) antagonist with an IC₅₀ and K_i of 0.25 and 3.7 nM, respectively.

HY-14369S

Elagolix-13C,d3 sodium NBI-56418-13C,d3 sodium	Isotope-Labeled Compounds GnRH Receptor	Endocrinology Cancer
Elagolix- ¹³C,d₃ (sodium) is the ¹³C- and deuterium labeled Elagolix sodium. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.

HY-P3672

[D-Ala6]-LH-RH	GnRH Receptor	Endocrinology
[D-Ala6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Ala6]-LH-RH acts as a *GnRH receptor* agonist .

HY-P3317

Azaline Azaline A	GnRH Receptor	Endocrinology
Azaline (Azaline A) is a gonadotropin-releasing hormone (GnRH) receptor antagonist with a K_D value of 0.48 nM. Azaline can effectively induce histamine release, with an effect comparable to that of GnRH, and it can completely inhibit ovulation at a dose of 2.0-3.0 μg per female rat. Azaline has potential applications in regulating reproductive functions .

HY-14789R

(R)-Elagolix (Standard) NBI-56418 (Standard)	GnRH Receptor Nuclear Factor of activated T Cells (NFAT) Reference Standards	Endocrinology Cancer
(R)-Elagolix (Standard) is the analytical standard of (R)-Elagolix. This product is intended for research and analytical applications. Elagolix is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (KD = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .

HY-P3671

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH	GnRH Receptor	Endocrinology
[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a *GnRH receptor* antagonist .

HY-W751574

Elagolix-d6 sodium NBI-56418-d6 sodium	Isotope-Labeled Compounds Nuclear Factor of activated T Cells (NFAT) GnRH Receptor	Endocrinology Cancer
Elagolix-d₆ (sodium) (NBI-56418-d₆ (sodium)) is deuterium labeled Elagolix sodium. Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (K_D = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .

HY-117982

SKI2496	GnRH Receptor ERK	Endocrinology
SKI2496 is an orally active *GnRH receptor* antagonist (IC₅₀: 0.25 nM for hGnRHR, 13.2 nM for monkey GnRHR, 279.2 nM for rat GnRHR). SKI2496 blocks Ca ²⁺ flux with an IC₅₀ value of 0.76 nM. SKI2496 inhibits ERK1/2 phosphorylation with an IC₅₀ value of 2.6 nM. SKI2496 inhbits serum LH concentrations, and can be used for research of sex hormone-dependent disorders .

HY-P2446

ORG 30276 APTAA-LHRH	GnRH Receptor	Endocrinology
ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.

HY-115633

Elagolix	GnRH Receptor Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease Cancer
Elagolix is an orally active, highly effective, selective and non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (K_D = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis .

HY-115633S

Elagolix-d9	Isotope-Labeled Compounds Nuclear Factor of activated T Cells (NFAT) GnRH Receptor	Metabolic Disease Cancer
Elagolix-d₉ is the deuterium labeled Elagolix. Elagolix sodium is a highly effective, selective, oral-active, short-term, non-peptide gonadotropin-releasing hormone receptor (GnRH receptor) antagonist (K_D = 54 pM) and NFAT inhibitor, which can be used to study pain related to endometriosis. .

Cat. No.	Product Name

HY-L047

Endocrinology Compound Library	1,050 compounds
The endocrine system is a chemical messenger system comprising feedback loops of the hormones released by internal glands of an organism directly into the circulatory system, regulating distant target organs. Hormones are chemicals that serve to communicate between organs and tissues for physiological regulation and behavioral activities. Hormones affect distant cells by binding to specific receptor proteins in the target cell, resulting in a change in cell function. The endocrine system is concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Irregulated hormone release, inappropriate response to signaling or lack of a gland can lead to endocrine disease. MCE offers a unique collection of 1,050 endocrinology related compounds targeting varieties of hormone receptors such as thyroid hormone receptor, TSH receptor, GNRH receptor, adrenergic receptor, etc. MCE Endocrinology Compound Library is a useful tool for the discovery of endocrinology drugs.

Endocrinology Compound Library

1,050 compounds

The endocrine system is a chemical messenger system comprising feedback loops of the hormones released by internal glands of an organism directly into the circulatory system, regulating distant target organs. Hormones are chemicals that serve to communicate between organs and tissues for physiological regulation and behavioral activities. Hormones affect distant cells by binding to specific receptor proteins in the target cell, resulting in a change in cell function.

The endocrine system is concerned with the integration of developmental events proliferation, growth, and differentiation, and the psychological or behavioral activities of metabolism, growth and development, tissue function, sleep, digestion, respiration, excretion, mood, stress, lactation, movement, reproduction, and sensory perception caused by hormones. Irregulated hormone release, inappropriate response to signaling or lack of a gland can lead to endocrine disease.

MCE offers a unique collection of 1,050 endocrinology related compounds targeting varieties of hormone receptors such as thyroid hormone receptor, TSH receptor, GNRH receptor, adrenergic receptor, etc. MCE Endocrinology Compound Library is a useful tool for the discovery of endocrinology drugs.

Cat. No.	Product Name	Target	Research Area